BioPharmSignal logoBioPharmSignal

Biotech News

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

Recursion (RXRX)RecursionEarnings

Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, announced today it will provide business updates and report its third quarter 2026 financial results on Monday, November 2, 2026, after the close of the financial markets, with live call from the Collaborative Group of the Americas on Inherited Gastrointestinal Cancer (CGA-IGC) Annual Meeting in Denver, Colorado on November 3, 2026, at 8:00 AM ET / 6:00 AM MT / 1:00 PM GMT.

Related news

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

RXRXRecursion2026-08-05 10:30 EST

Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program

ADMAADMA Biologics2026-10-28 11:00 EST

ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026

CHRSCoherus BioSciences, Inc.2026-10-26 13:30 EST

Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026

MDXGMiMedx2026-10-14 20:01 EST

MIMEDX to Host Third Quarter 2026 Operating and Financial Results Conference Call on October 28, 2026

MDXGMiMedx2026-07-20 12:00 EST

MIMEDX to Host Second Quarter 2026 Operating and Financial Results Conference Call on July 29

ALVOAlvotech2026-10-28 11:00 EST

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

IBIOIbio Inc2026-08-28 11:00 EST

iBio Reports Fiscal Year 2026 Financial Results and Provides Corporate Update

STTKShattuck Labs2026-08-11 10:15 EST

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

ALVOAlvotech2026-08-10 12:00 EST

Alvotech to Report Financial Results for H1 2026

View all latest news

Recursion

AI-Native Drug Discovery Recursion is a clinical-stage TechBio company using an integrated discovery and development platform to generate medicines across oncology, rare disease, neuroscience and immunology. The Recursion OS combines proprietary multimodal biological and chemical data, purpose-built AI models and experimental...

Recent company news

RXRXRecursion2026-11-02 21:30 EST

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

RXRXRecursion2026-11-02 21:25 EST

New Phase 2 REC-4881 Data Presented at CGA-IGC Show Deep, Durable Polyp Burden Reductions in FAP, with Activity Across the GI Tract and in Larger, Higher-Risk Polyps

RXRXRecursion2026-11-02 21:05 EST

Recursion Appoints Fred Hassan as Chair of the Board

RXRXRecursion2026-10-26 20:05 EST

Recursion to Host Webinar Focused on Updated REC-4881 (FAP) Data from CGA-IGC on Tuesday, November 3

RXRXRecursion2026-10-15 12:45 EST

Recursion Announces Sanofi Options Potential First-in-Class Immunology Development Candidate from Their Collaboration

Stock data

Close
3.50 USD
Market cap
1.92B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States